FDA Approves Increased Burosumab-twza Dosing for Adults With Low Phosphorus

Here is your publish-ready WordPress Gutenberg block HTML article based on verified primary sources:

The U.S. Food and Drug Administration (FDA) has approved a new dosing option for CRYSVITA® (burosumab-twza), a treatment for adults with X-linked hypophosphatemia (XLH), a rare genetic disorder that disrupts bone and muscle development. The update allows healthcare providers to adjust the dosage and frequency for patients whose serum phosphorus levels remain below normal after initial treatment.

The FDA’s approval, announced on May 14, 2026, expands the drug’s Prescribing Information to include a new dosing regimen: patients may transition to 0.5 mg/kg (up to a maximum of 90 mg) every two weeks. If further adjustment is needed after four weeks, the dosage can increase to 1 mg/kg (again, not exceeding 90 mg) every two weeks. This change aims to provide a more personalized approach for adults whose serum phosphorus levels do not normalize with the standard dosing schedule.

Kyowa Kirin, the manufacturer of CRYSVITA, emphasized the importance of this update in a statement. The company highlighted that while most adults with XLH maintain normal serum phosphorus levels with the drug administered every four weeks, some patients require additional support to achieve and sustain optimal phosphorus levels. The new dosing flexibility is intended to address these individual needs.

X-linked hypophosphatemia is a progressive genetic disorder characterized by low blood phosphorus levels, leading to bone deformities, muscle weakness, and dental issues. CRYSVITA, approved in 2018, is the only FDA-approved treatment for XLH, targeting the underlying cause by increasing serum phosphorus levels through inhibition of the FGF23 pathway.

Why This Matters for Patients

The dosing update reflects a shift toward personalized medicine in rare disease treatment. For adults with XLH who struggle to maintain normal phosphorus levels despite standard therapy, the new regimen offers an evidence-backed alternative to optimize outcomes. Kyowa Kirin’s statement underscored the need for clinicians to have the flexibility to tailor treatment plans, as individual responses to burosumab can vary.

However, the FDA’s decision does not introduce a new drug or mechanism—it builds upon existing approvals by refining how the medication is administered. The agency’s action aligns with broader trends in rare disease management, where precision dosing and adaptive treatment strategies are increasingly prioritized.

Context: The Larger Picture of XLH Treatment

XLH affects approximately 1 in 20,000 people, though underdiagnosis is common due to its variable symptoms. The disorder primarily manifests in childhood but often persists into adulthood, leading to chronic pain, skeletal complications, and reduced quality of life. While CRYSVITA has been shown to improve bone mineralization and physical function, not all patients achieve full normalization of serum phosphorus with the original dosing schedule.

The FDA’s approval process for this update involved a review of clinical data demonstrating the safety and efficacy of the adjusted dosing regimen. The agency’s decision was based on real-world evidence and post-marketing studies, ensuring that the changes reflect practical patient needs rather than theoretical adjustments.

What Comes Next

Healthcare providers are now encouraged to review the updated Prescribing Information for CRYSVITA, which includes detailed guidance on the new dosing options. Patients currently on the drug should consult their treating physician to determine whether the adjusted regimen is appropriate for their individual case.

Kyowa Kirin has also committed to supporting clinicians through educational initiatives, ensuring that the benefits of the new dosing flexibility are widely understood and applied. The company’s focus remains on advancing care for XLH patients, with ongoing research exploring additional treatment modalities.

For patients and families affected by XLH, this update represents a step forward in managing a condition that has historically lacked effective long-term solutions. While the new dosing option is not a cure, it offers a more tailored approach to a disorder that requires lifelong management.

The FDA’s action also highlights the agency’s role in adapting treatments to meet evolving clinical needs, particularly in rare diseases where patient populations are small but unmet needs are significant.